FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3045928211> ?p ?o ?g. }

• W3045928211 endingPage "175" @default.
• W3045928211 startingPage "164" @default.
• W3045928211 abstract "Background Relevance of antiangiogenic treatment with bevacizumab in patients with glioblastoma is controversial because progression-free survival benefit did not translate into an overall survival (OS) benefit in randomized phase III trials. Purpose To perform longitudinal characterization of intratumoral angiogenesis and oxygenation by using dynamic susceptibility contrast agent–enhanced (DSC) MRI and evaluate its potential for predicting outcome from administration of bevacizumab. Materials and Methods In this secondary analysis of the prospective randomized phase II/III European Organization for Research and Treatment of Cancer 26101 trial conducted between October 2011 and December 2015 in 596 patients with first recurrence of glioblastoma, the subset of patients with availability of anatomic MRI and DSC MRI at baseline and first follow-up was analyzed. Patients were allocated into those administered bevacizumab (hereafter, the BEV group; either bevacizumab monotherapy or bevacizumab with lomustine) and those not administered bevacizumab (hereafter, the non-BEV group with lomustine monotherapy). Contrast-enhanced tumor volume, noncontrast-enhanced T2 fluid-attenuated inversion recovery (FLAIR) signal abnormality volume, Gaussian-normalized relative cerebral blood volume (nrCBV), Gaussian-normalized relative blood flow (nrCBF), and tumor metabolic rate of oxygen (nTMRO2) was quantified. The predictive ability of these imaging parameters was assessed with multivariable Cox regression and formal interaction testing. Results A total of 254 of 596 patients were evaluated (mean age, 57 years ± 11; 155 men; 161 in the BEV group and 93 in non-BEV group). Progression-free survival was longer in the BEV group (3.7 months; 95% confidence interval [CI]: 3.0, 4.2) compared with the non-BEV group (2.5 months; 95% CI: 1.5, 2.9; P = .01), whereas OS was not different (P = .15). The nrCBV decreased for the BEV group (−16.3%; interquartile range [IQR], −39.5% to 12.0%; P = .01), but not for the non-BEV group (1.2%; IQR, −17.9% to 23.3%; P = .19) between baseline and first follow-up. An identical pattern was observed for both nrCBF and nTMRO2 values. Contrast-enhanced tumor and noncontrast-enhanced T2 FLAIR signal abnormality volumes decreased for the BEV group (−66% [IQR, −83% to −35%] and −33% [IQR, −71% to −5%], respectively; P < .001 for both), whereas they increased for the non-BEV group (30% [IQR, −17% to 98%], P = .001; and 10% [IQR, −13% to 82%], P = .02, respectively) between baseline and first follow-up. None of the assessed MRI parameters were predictive for OS in the BEV group. Conclusion Bevacizumab treatment decreased tumor volumes, angiogenesis, and oxygenation, thereby reflecting its effectiveness for extending progression-free survival; however, these parameters were not predictive of overall survival (OS), which highlighted the challenges of identifying patients that derive an OS benefit from bevacizumab. © RSNA, 2020 Online supplemental material is available for this article. See also the editorial by Dillon in this issue." @default.
• W3045928211 created "2020-08-03" @default.
• W3045928211 creator A5000010107 @default.
• W3045928211 creator A5001693892 @default.
• W3045928211 creator A5014451875 @default.
• W3045928211 creator A5017177249 @default.
• W3045928211 creator A5018771146 @default.
• W3045928211 creator A5019876508 @default.
• W3045928211 creator A5027292126 @default.
• W3045928211 creator A5028806143 @default.
• W3045928211 creator A5033807586 @default.
• W3045928211 creator A5038129366 @default.
• W3045928211 creator A5038487968 @default.
• W3045928211 creator A5040945122 @default.
• W3045928211 creator A5051810091 @default.
• W3045928211 creator A5052657395 @default.
• W3045928211 creator A5063978061 @default.
• W3045928211 creator A5064778456 @default.
• W3045928211 creator A5070756414 @default.
• W3045928211 creator A5072647800 @default.
• W3045928211 creator A5079482117 @default.
• W3045928211 creator A5080482957 @default.
• W3045928211 creator A5080490475 @default.
• W3045928211 creator A5090306990 @default.
• W3045928211 date "2020-10-01" @default.
• W3045928211 modified "2023-10-15" @default.
• W3045928211 title "Noninvasive Characterization of Tumor Angiogenesis and Oxygenation in Bevacizumab-treated Recurrent Glioblastoma by Using Dynamic Susceptibility MRI: Secondary Analysis of the European Organization for Research and Treatment of Cancer 26101 Trial" @default.
• W3045928211 cites W1536103630 @default.
• W3045928211 cites W2064360454 @default.
• W3045928211 cites W2076269412 @default.
• W3045928211 cites W2088952991 @default.
• W3045928211 cites W2108518808 @default.
• W3045928211 cites W2123021957 @default.
• W3045928211 cites W2124736921 @default.
• W3045928211 cites W2125734180 @default.
• W3045928211 cites W2132697290 @default.
• W3045928211 cites W2134420328 @default.
• W3045928211 cites W2142104626 @default.
• W3045928211 cites W2144487043 @default.
• W3045928211 cites W2146628652 @default.
• W3045928211 cites W2156330848 @default.
• W3045928211 cites W2158303916 @default.
• W3045928211 cites W2159538968 @default.
• W3045928211 cites W2162643152 @default.
• W3045928211 cites W2170367762 @default.
• W3045928211 cites W2173909848 @default.
• W3045928211 cites W2195297470 @default.
• W3045928211 cites W2265986496 @default.
• W3045928211 cites W2510787410 @default.
• W3045928211 cites W2512098582 @default.
• W3045928211 cites W2768388636 @default.
• W3045928211 cites W2795436270 @default.
• W3045928211 cites W2884829270 @default.
• W3045928211 cites W2895294558 @default.
• W3045928211 cites W2928374940 @default.
• W3045928211 cites W2968446587 @default.
• W3045928211 cites W2986796977 @default.
• W3045928211 doi "https://doi.org/10.1148/radiol.2020200978" @default.
• W3045928211 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32720870" @default.
• W3045928211 hasPublicationYear "2020" @default.
• W3045928211 type Work @default.
• W3045928211 sameAs 3045928211 @default.
• W3045928211 citedByCount "15" @default.
• W3045928211 countsByYear W30459282112020 @default.
• W3045928211 countsByYear W30459282112021 @default.
• W3045928211 countsByYear W30459282112022 @default.
• W3045928211 countsByYear W30459282112023 @default.
• W3045928211 crossrefType "journal-article" @default.
• W3045928211 hasAuthorship W3045928211A5000010107 @default.
• W3045928211 hasAuthorship W3045928211A5001693892 @default.
• W3045928211 hasAuthorship W3045928211A5014451875 @default.
• W3045928211 hasAuthorship W3045928211A5017177249 @default.
• W3045928211 hasAuthorship W3045928211A5018771146 @default.
• W3045928211 hasAuthorship W3045928211A5019876508 @default.
• W3045928211 hasAuthorship W3045928211A5027292126 @default.
• W3045928211 hasAuthorship W3045928211A5028806143 @default.
• W3045928211 hasAuthorship W3045928211A5033807586 @default.
• W3045928211 hasAuthorship W3045928211A5038129366 @default.
• W3045928211 hasAuthorship W3045928211A5038487968 @default.
• W3045928211 hasAuthorship W3045928211A5040945122 @default.
• W3045928211 hasAuthorship W3045928211A5051810091 @default.
• W3045928211 hasAuthorship W3045928211A5052657395 @default.
• W3045928211 hasAuthorship W3045928211A5063978061 @default.
• W3045928211 hasAuthorship W3045928211A5064778456 @default.
• W3045928211 hasAuthorship W3045928211A5070756414 @default.
• W3045928211 hasAuthorship W3045928211A5072647800 @default.
• W3045928211 hasAuthorship W3045928211A5079482117 @default.
• W3045928211 hasAuthorship W3045928211A5080482957 @default.
• W3045928211 hasAuthorship W3045928211A5080490475 @default.
• W3045928211 hasAuthorship W3045928211A5090306990 @default.
• W3045928211 hasBestOaLocation W30459282112 @default.
• W3045928211 hasConcept C101070640 @default.
• W3045928211 hasConcept C126322002 @default.
• W3045928211 hasConcept C126838900 @default.
• W3045928211 hasConcept C143409427 @default.
• W3045928211 hasConcept C143998085 @default.
• W3045928211 hasConcept C168563851 @default.
• W3045928211 hasConcept C2776694085 @default.

• next